chief executive officer (CEO) and representative director, when Mr. Weber retires from the company in June 2026. Mrs. Kim will be proposed as a candidate for election to the Board at Takeda’s ...

Hillenbrand Inc. has announced the sale of a 51 percent stake in its Milacron business to Bain Capital, a leading private ...

Guidance to Reflect Transaction; Maintains Outlook for Remaining Businesses BATESVILLE, Ind., Feb. 5, 2025 /PRNewswire/ -- Hillenbrand, Inc. (NYSE: ...

Hillenbrand Inc. has announced plans to sell a 51 percent stake in its Cincinnati-based subsidiary Milacron LLC, to an affiliate of Boston-based investment firm Bain Capital. Hillenbrand, which is ...

Hillenbrand Inc. has announced the sale of a 51 percent stake in its Milacron injection molding and extrusion machinery ...

Industrial processing equipment and solutions provider Hillenbrand (NYSE:HI) beat Wall Street’s revenue expectations in Q4 ...

Hillenbrand Inc. has announced the sale of a 51% stake in its Milacron injection molding and extrusion business to an ...

Reports Q1 revenue $707M, consensus $695.46M. “We delivered first quarter results in line with our expectations, with continued momentum in ...

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

Julie Kim is set to replace Christophe Weber as the new chief executive officer of Takeda Pharmaceutical Co., becoming the first woman to lead the more than 240-year-old Japanese drugmaker.